Literature DB >> 15308731

Induction of cellular immune responses to simian immunodeficiency virus gag by two recombinant negative-strand RNA virus vectors.

Yurie Nakaya1, Takaaki Nakaya, Man-Seong Park, Jerome Cros, Jiro Imanishi, Peter Palese, Adolfo García-Sastre.   

Abstract

A recombinant Newcastle disease virus (rNDV) expressing simian immunodeficiency virus (SIV) Gag protein (rNDV/SIVgag) was generated. The rNDV/SIVgag virus induced Gag-specific cellular immune responses in mice, leading to a specific anti-Gag antiviral immunity. This was evidenced by the inhibition of growth of recombinant vaccinia virus expressing an identical Gag antigen (rVac/SIVgag) but not of wild-type vaccinia virus in rNDV/SIVgag-immunized mice. Among intravenous, intraperitoneal, or intranasal immunization routes, intranasal administration induced the strongest protective response against challenge with rVac/SIVgag. We further demonstrated that these immune responses were greatly enhanced after booster immunization with recombinant influenza viruses expressing immunogenic portions of SIV Gag. The magnitude of the protective immune response correlated with the levels of cellular immune responses to Gag, which were still evident 9 weeks after immunization. These results suggest that rNDV and influenza virus vectors are suitable candidate vaccines against AIDS as well as against other infectious diseases.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15308731      PMCID： PMC506935          DOI： 10.1128/JVI.78.17.9366-9375.2004

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  53 in total

1.  Shared antigenic epitopes of the major core proteins of human and simian immunodeficiency virus isolates.

Authors:  J R Higgins; S Sutjipto; P A Marx; N C Pedersen
Journal:  J Med Primatol       Date:  1992-07       Impact factor: 0.667

2.  HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides.

Authors:  D F Nixon; A R Townsend; J G Elvin; C R Rizza; J Gallwey; A J McMichael
Journal:  Nature       Date:  1988-12-01       Impact factor: 49.962

3.  Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans.

Authors:  A Hoffenbach; P Langlade-Demoyen; G Dadaglio; E Vilmer; F Michel; C Mayaud; B Autran; F Plata
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

4.  At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells.

Authors:  M Kozak
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469

5.  CD8+ T cells from HIV-1-infected individuals inhibit acute infection by human and primate immunodeficiency viruses.

Authors:  C M Walker; G A Thomson-Honnebier; F C Hsueh; A L Erickson; L Z Pan; J A Levy
Journal:  Cell Immunol       Date:  1991-10-15       Impact factor: 4.868

6.  Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.

Authors:  Andrew L Pecora; Naiyer Rizvi; Gary I Cohen; Neal J Meropol; Daniel Sterman; John L Marshall; Stuart Goldberg; Peter Gross; James D O'Neil; William S Groene; M Scot Roberts; Harvey Rabin; Michael K Bamat; Robert M Lorence
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

7.  Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine.

Authors:  R B Belshe; E M Swierkosz; E L Anderson; F K Newman; S L Nugent; H F Maassab
Journal:  J Infect Dis       Date:  1992-04       Impact factor: 5.226

8.  Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.

Authors:  S Li; M Rodrigues; D Rodriguez; J R Rodriguez; M Esteban; P Palese; R S Nussenzweig; F Zavala
Journal:  Proc Natl Acad Sci U S A       Date:  1993-06-01       Impact factor: 11.205

9.  Attenuated veterinary virus vaccine for the treatment of cancer.

Authors:  L K Csatary; S Eckhardt; I Bukosza; F Czegledi; C Fenyvesi; P Gergely; B Bodey; C M Csatary
Journal:  Cancer Detect Prev       Date:  1993

Review 10.  Vaccines and vaccine strategies against HIV.

Authors:  Ivan Stratov; Robert DeRose; Damian F J Purcell; Stephen J Kent
Journal:  Curr Drug Targets       Date:  2004-01       Impact factor: 3.465
View more
  23 in total

1.  Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and cats.

Authors:  Jinying Ge; Xijun Wang; Lihong Tao; Zhiyuan Wen; Na Feng; Songtao Yang; Xianzhu Xia; Chinglai Yang; Hualan Chen; Zhigao Bu
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

Review 2.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

3.  Evaluation of humoral, mucosal, and cellular immune responses following co-immunization of HIV-1 Gag and Env proteins expressed by Newcastle disease virus.

Authors:  Sunil K Khattar; Senthilkumar Palaniyandi; Sweety Samal; Celia C LaBranche; David C Montefiori; Xiaoping Zhu; Siba K Samal
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.

Authors:  Zhu-Nan Li; Scott N Mueller; Ling Ye; Zhigao Bu; Chinglai Yang; Rafi Ahmed; David A Steinhauer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 5.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

6.  Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.

Authors:  Shin-Hee Kim; Shun Chen; Xi Jiang; Kim Y Green; Siba K Samal
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

7.  Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice.

Authors:  Jad Maamary; Frida Array; Qinshan Gao; Adolfo García-Sastre; Ralph M Steinman; Peter Palese; Godwin Nchinda
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

8.  Evaluation of recombinant influenza virus-simian immunodeficiency virus vaccines in macaques.

Authors:  Amy Sexton; Robert De Rose; Jeanette C Reece; Sheilajen Alcantara; Liyen Loh; Jessica M Moffat; Karen Laurie; Aeron Hurt; Peter C Doherty; Stephen J Turner; Stephen J Kent; John Stambas
Journal:  J Virol       Date:  2009-05-13       Impact factor: 5.103

9.  Recombinant Newcastle disease virus as a vaccine vector for cancer therapy.

Authors:  Adam Vigil; Osvaldo Martinez; Mark A Chua; Adolfo García-Sastre
Journal:  Mol Ther       Date:  2008-08-19       Impact factor: 11.454

10.  Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans.

Authors:  Joshua M DiNapoli; Jerrold M Ward; Lily Cheng; Lijuan Yang; Subbiah Elankumaran; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  Vaccine       Date:  2009-01-23       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.